Hetero

A
Project report
ON
AWARENESS AND TREATMENT TRENDS AMONGST GENERAL
PHYSICIANS ABOUT BENIGN PROSTATE HYPERPLASIA (BPH) AND OVER
ACTIVE BLADDER (OAB)
For
HETERO HEALTHCARE LTD.
In partial fulfillment of the requirements of
Master of Management Studies
Conducted by
University of Mumbai
Rizvi Institute of Management Studies & Research
Under the guidance of

Prof. Rajesh Vyas
Submitted by
Zeeshan Kamruddin Shaikh
MMS
Batch: 2014 2016.
ACKNOWLEDGEMENT
The research on Awareness and Treatment trends amongst General Physicians

about Benign Prostate Hyperplasia (BPH) and Over Active Bladder (OAB)
IT has been given to me as part of the summer project from Hetero Healthcare Ltd. I have
tried my best to present this information as clearly as possible using basic terms that I
hope will be comprehended by the widest spectrum of researchers, analysts and students
for further studies.
I am highly indebted to Prof. Rajesh Vyas for his guidance and constant
supervision as well as for providing necessary information regarding the project & also
for their support in completing the project.
I would like to express my gratitude towards employee of Hetero Healthcare Ltd.
for their kind co-operation and encouragement which help me in completion of this
project.
I would like to express my special gratitude and thanks to Ms. Bella Barve of
Hetero Healthcare Ltd. for giving me such attention and time.
I am grateful to all faculty members of Rizvi Institute of Management and my friends
who have helped me in the successful completion of this project.
CERTIFICATE
This is to certify that Mr. Zeeshan Kamruddin Shaikh, a student of Rizvi Institute of
Management studies and Research, of MMS III bearing Roll No. 121 and specializing in
Marketing has successfully completed the project titled
Awareness and Treatment trends amongst General Physicians about Benign

Prostate Hyperplasia (BPH) and Over Active Bladder (OAB)
Under the guidance of Prof. Rajesh Vyas in partial fulfillment of the requirement of
Master of Management Studies by the University of Mumbai for the academic year 2014
2016.
______________
Prof. Rajesh Vyas
Project Guide
______________
Prof. Umar Farooq
Academic Coordinator
______________
Dr. Kalim Khan
Director
TABLE OF CONTENT
Sr. No
Particulars
Pg. No
Executive Summary
Background of Pharma Industry
Introduction to Hetero Healthcare Limited
SWOT Analysis of Hetero Healthcare
37
SWO T Analysis of Pfizer Limited
39
Data Analysis & Interpretation
41
Questionnaire & Analysis
42
Findings
51
Strategy
52
10
Conclusion
53
11
Bibliography
54
LIST OF TABLES
Particulars
Table 1: Products/Drugs by Hetero Healthcare Ltd
Table 2: Technical Packages by Hetero Healthcare Ltd
Page No.
17 -29
30-32
LIST OF FIGURES
Particulars
Figure 1: Count of Patients Suffering from BPH & OAB
Figure 2: Diagnostic Procedure for BPH
Figure 3: Diagnostic Procedure for OAB
Figure 4: Line of Treatment
Figure 5: Molecules used by GPs for BPH
Figure 6: Molecules used by GPs for OAB
Figure 7: Dosage and Period Molecule for BPH
Figure 8: Dosage and Period Molecule for OAB
Figure 9: Awareness among GPs regarding BPH & OAB
Page No.
42
43
44
45
46
47
48
49
50
Awareness and Treatment trends amongst General Physicians about Benign Prostate Hyperplasia
(BPH) and Over Active Bladder (OAB)
EXECUTIVE SUMMARY
Hetero drugs Limited (Hetero) is a research based pharmaceutical company. It undertakes
the research, development, manufacturing and marketing of active pharmaceutical
ingredients (APIs), intermediate chemicals and finished dosages. The company focuses
on the development and manufacturing of bio-generics and offers custom research and
manufacturing services (CRAMS) to global biotech and pharmaceutical companies.
Hetero owns and operates through its 18 manufacturing facilities that are approved by the
US FDA, Spanish Agency of Medicines & Health care products, WHO-Geneva,
ANVISA-Brazil, and IDA-Netherlands, among others. It markets its products in more
than 138 countries across the globe. Hetero is headquartered in Hyderabad, Telangana,
India.
Hetero Drugs Limited Pharmaceuticals & Healthcare Deals and Alliances Profile
provides you comprehensive data and trend analysis of the companys Mergers and
Acquisitions (M&As), partnerships and financings. The report provides detailed
information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture
Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value
categorized into deal types, sub-sector and regions.
This project is conducted to study about popular molecules used in a treatment of Benign
Prostate Hyperplasia (BPH) and Over Active Bladder (OAB):
Benign Prostate Hyperplasia:

Benign Prostatic Hyperplasia (BPH) also called benign enlargement of the prostate (BEP)
or (BPE), adenofibromyomatous hyperplasia and benign prostatic hypertrophy is a
benign increase in a size of prostate.
BPH involves hyperplasia of prostatic stromal and epithelial cells, resulting in the
formation of large, fairly discrete nodules in the transition zone of the prostate. When
1
sufficiently large, the nodules impinge on the urethra and increase resistance to flow
of urine from the bladder. This is commonly referred to as "obstruction," although the
urethral lumen is no fewer patents, only compressed. Resistance to urine flow requires
the bladder to work harder during voiding, possibly leading to progressive hypertrophy,
instability, or weakness (atony) of the bladder muscle. Although prostate specific
antigen levels may be elevated in these patients because of increased organ volume
and inflammation due to urinary tract infections, BPH does not lead to cancer or increase
the risk of cancer.
BPH involves hyperplasia (an increase in the number of cells) rather than hypertrophy (a
growth in the size of individual cells), but the two terms are often used interchangeably,
even amongst urologists.
Adenomatous prostatic growth is believed to begin at approximately age 30 years. An
estimated 50% of men have histological evidence of BPH by age 50 years and 75% by
age 80 years; in 40-50% of these men, BPH becomes clinically significant. BPH was one
of the ten most prominent and costly diseases in men older than 50 years of age in a study
in the United States.
Over Active Bladder:
Overactive bladder (OAB), also known as overactive bladder syndrome, is a condition
where there is a frequent feeling of needing to urinate to a degree that it negatively affects
a person's life. The frequent need to pee may occur during the day, at night, or both. If
there is loss of bladder control than it is known as urge incontinence. More than 40% of
people with overactive bladder have incontinence. While about 40% to 70%
of incontinence is due to overactive bladder. It is not life-threatening. Most with the
condition have problems for years.
The cause of overactive bladder is unknown. Risk factors include obesity, caffeine,
and constipation. Poorly controlled diabetes, poor mobility, and chronic pelvic pain may
worsen the symptoms. People often have the symptoms for a long time before seeking
treatment and the condition is sometimes identified by caregivers. Diagnosis is based on a
person's signs and symptoms and requires other problems such as urinary tract
2
infections or neurological conditions to be excluded. The amount of urine passed during

each urination is relatively small. Pain while urinating suggests that there is a problem
other than overactive bladder.
Overactive bladder is estimated to occur in 7-27% of men and 9-43% of women. It
becomes more common with age. Some studies suggest that the condition is more
common in women, especially when associated with loss of bladder control
A survey was conducted wherein primary data was collected from General Physician
(MBBS) to understand how frequently Doctors deal with such patients, the survey was
conducted for 40 days in the areas of western and central Mumbai wherein Doctors
feedback was taken.
The observation from the survey was female Doctor dont treat the patients of Benign
Prostate Hyperplasia. Tamsolusin with the combination of Dutasteride is used largely for
both the disease whereas these molecules are in market since past 10 years.
The most commonly observed symptoms for Benign Prostate Hyperplasia (BPH) were
Micturition, Nocturia, Urge Incontinence, Haemeturia and inflamed urination.
The most commonly observed symptoms for Over Active Bladder (OAB) were urgency
in urination, micturition, frequent urination, Increased frequency of urination.
3
BACKGROUND OF PHARMA INDUSTRY

Exports of pharmaceutical products from India increased from US$6.23 billion in 2006
07. The pharmaceutical industry in India is the world's third-largest in terms of volume.
According to the Department of Pharmaceuticals of the Indian Ministry of Chemicals and
Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and
September 2009 was US$21.04 billion. The domestic market was worth US$12.26
billion. The industry has a market share of $14 billion in the United States.
According to the India Brand Equity Foundation, the Indian pharmaceutical market is
likely to grow at a compound annual growth rate (CAGR) of 14-17 per cent in between
2012-16.India is now among the top five pharmaceutical emerging markets of the world.
The government began encouraging the growth of drug manufacturing by Indian
companies in the early 1960s, and with the Patents Act in 1970. This patent act removed
composition patents from foods and drugs, and though it kept process patents, these were
shortened to a period of five to seven years.
The lack of patent protection made the Indian market undesirable to the multinational
companies that had dominated the market and as they left, Indian companies carved a
niche in both the Indian and world markets by reverse-engineering new processes for
manufacturing low-cost drugs. Although some of the larger companies have taken baby
steps towards drug innovation, the industry as a whole has not changed its business
model.
In 2009-10, India's biopharmaceutical industry grew at 17 percent, with revenues of Rs.
137 billion ($3 billion). Bio-pharma was the biggest contributor, generating 60 percent of
the industry's growth at Rs. 88.29 billion, followed by bio-services at Rs. 26.39 billion
and bio-agriculture at Rs. 19.36 billion.
In 2013, there were 4,655 pharmaceutical manufacturing plants in India, employing over
345 thousand workers.
4
Challenges:
Even after the increased investment, market leaders such as Sun Pharma and Dr. Reddys
Laboratories spent only 510% of their revenues on R&D, lagging behind Western
pharmaceuticals like Pfizer, whose research budget last year was greater than the
combined revenues of the entire Indian pharmaceutical industry.
This disparity is too great to be explained by cost differentials, and it comes when
advances in genomics have made research equipment more expensive than ever.
The drug discovery process is further hindered by a dearth of qualified molecular
biologists. Due to the disconnect between curriculum and industry, pharma in India have
so far lacked the academic collaboration that is crucial to drug development in the West.
Pharmaceutical and Biotechnology:
Unlike in other countries, the difference between biotechnology and pharmaceuticals
remains well-defined in India. Bio-tech there still plays the role of pharmas little sister,
but many outsiders have high expectations for the future. India accounted for 2% of the
$41 billion global biotech market and in 2003 was ranked 3rd in the Asia-Pacific region
and 11th in the world in number of biotech. In 2004-5, the Indian biotech industry saw its
revenues grow 37% to $1.1 billion. 75% of 20045 revenues came from biopharmaceuticals, which saw 30% growth last year. Of the revenues from biopharmaceuticals, vaccines led the way, comprising 47% of sales. Biologics and largemolecule drugs tend to be more expensive than small-molecule drugs, and India hopes to
sweep the market in bio-generics and contract manufacturing as drugs go off patent and
Indian companies upgrade their manufacturing capabilities.
Most companies in the biotech sector are extremely small, with only two firms breaking
100 million dollars in revenues. At last count there were 265 firms registered in India,
over 75% of which were incorporated in the last five years. The newness of the
companies explains the industrys high consolidation in both physical and financial
terms. Almost 50% of all biotech are in or around Bangalore, and the top ten companies
captured 47% of the market. The top five companies were homegrown; Indian firms
5
account for 62% of the bio-pharma sector and 52% of the industry as a whole.[4,46] The
Association of Biotechnology-Led Enterprises (ABLE) is aiming to grow the industry to
$5 billion in revenues generated by 1 million employees by 2009, and data from the
Confederation of Indian Industry (CII) seem to suggest that it is possible.
6
INTRODUCTION TO HETERO HEALTHCARE LIMITED
Hetero is a research based global pharmaceutical company focused on development,

manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate
Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a
tradition of excellence and deep sense of commitment in developing cost effective
processes to offer wide range of affordable drugs.
Hetero is building on the strengths of vertical integration in discovery research, process
chemistry, API manufacturing, formulation development and commercialization. Hetero
is a leading international supplier with a rich portfolio of over 200 products from wide
range of therapeutic categories both in active pharmaceutical ingredients and finished
dosages.
Heteros manufacturing facilities are cGMP compliant meeting global standards in terms
of infrastructure and systems. Majority of them are approved by the various regulatory
authorities of USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines &
health care products, ANVISA-Brazil, IDA-Netherlands etc.,
With full-fledged marketing capabilities, the company has been able to market its
products in over 138 countries across the globe.
7
FOUNDER
Dr. Bandi Parthasaradhi Reddy, Chairman & Managing Director of Hetero group is
academically endowed with a Post Graduate and Doctoral degrees with distinction in the
field of synthetic chemistry. Prior to founding of Hetero Drugs Limited, Dr. B.P.S Reddy
had a stint in leading pharmaceutical companies as the head of the Research &
Development division. His sharp analysis and ability to synthesize various chemical
compounds lead to the discovery of new processes, cost effective schemes for
manufacturing of various pharmaceutical products. During the said period Dr.B.P.S
Reddy has the credit of introducing many new molecules for the first time in Indian
pharmaceutical market.
A visionary the world knows as Dr. B.P.S.Reddy, is the driving force behind this growing
pharmaceutical phenomenon called HETERO. Dr.B.P.S.Reddys dream child, Hetero
was born in the year 1993 as a small API unit. Today, 17 years later, the name is
synonymous with leadership in pharmaceuticals with more than 18 manufacturing units
and 8000 employees. An entity that is grown in stature by virtue of its combined strength
in research, manufacturing and marketing.
Dr. B.P.S.Reddy steered Hetero towards the forefront of global pharmaceutical industry
with his vision to be recognised as an aggressive company that combines its strength of
R&D and manufacturing with definite advantages in terms of cost and chemistry with a
strong emphasis on quality of the products.
Dr. B.P.S.Reddy is now focusing on giving new dimensions to Hetero in terms of
research and innovation programs in discovery research to take the company to greater
heights.
8
AWARDS AND ACCOLADES

Hetero has been scaling new heights on a continual basis. These achievements have been
the result of concerted efforts on the part of different functions within the organisation to
achieve the organisational goal of being a leader.
In its path to success, Hetero has seen many a milestone being crossed and achieved
many awards on various fronts. Awards for exemplary work in R&D and marketing are
just a few to name.
A track of few events that saw Hetero reaching its Zenith of glory is:
2009
Top Pharmexcil Gold Patent award.
Top Pharmexcil Outstanding Export Performance award in Drugs and

Pharmaceuticals.
2006
Chemexil Trishul export award for outstanding export performance 2001

Excellence & National Integration award in recognition of the efforts for
excellence with affairs connected with educational specialties and creating
teaching skills besides promoting harmony at all levels in the college.
1999
Highest exporter award against stiff competition from internationally recognized

domestic competitors.
9
1998
Top Chemexil award for Exports.
1996
National award for "Best Efforts in Research and Development" from the
Department of Scientific and Industrial Research, Ministry of Science and
Technology, Government of India, in the year 1996.
GLOBAL PRESENCE
Hetero exports its products across different regions USA, Canada, Europe, Japan, Latin
America, Africa, Middle East, Far East, Australia, Russia & CIS, in the world and is
catering to the requirements of around 138 countries in the world.
CORPORATE SOCIAL RESPONSIBILITY

Corporate Social Responsibility is our commitment
Hetero Group always believes in the concept of giving back to the society to uplift the
living standards in the surrounding society as one of the prime responsibilities and always
took the lead. The Group is committed for implementation of various CSR initiatives and
contributes substantially to the cause.
Hetero Group received appreciation from the Government of Andhra Pradesh, for its
outstanding contribution in the implementation of Corporate Social Responsibility. .
Environment Protection:
Completed One Million Plantation Programme.
Taking up Plantation in the surrounding Schools.
Completed Plantation in newly acquired 15 acres land and a total of 25000 Nos.
of saplings made.
10
Provided substantial amount to the industrial association for the development of

infrastructure and environment in Kazipally IDA.
Provision of Biomass Pellets for cooking purpose in place of LPG gas.
Social Welfare Programs:

Hetero recognizes its obligations towards the society and as a socially responsible
organization, we strive to take care of the less privileged sections of our society. We
extend our expertise to transform the lives of our people and make a difference to the
society. In this initiative, Hetero has adopted few villages for their overall development.
Education
Sports
Medical
Rural Development
1) Education: Hetero assists in setting up of schools for children in the vicinity of the
plants, where there is no access to education facilities, providing financial
assistance to the poor students who have promising academic record and adopts
schools for the following support:
Infrastructure: Construction and renovation of schools, classrooms, libraries,

provision of amenities like class room benches, tables and chairs, sanitation
facilities and constructing compound walls for the surrounding schools.
Distribution of booksand reading materials to the school libraries along with

books and uniforms to the school going children.
Awarding of Merit scholarships to students and provision of free technical

education in engineering on the eligibility basis.
11
2) Sports: Sponsors athletes from various educational institutions to participate in

National and International level competitions, organises sports camps and events in many
villages.
3) Medical: Hetero conducts periodical medical camps at various locations in socially
backward areas to provide timely medical assistance to the needy. Hetero also contributes
for the construction of health centers and has liberally donated medicines to the
Government of India, Government of A.P. and to various Hospitals.
4) Rural Infrastructure: Hetero adopts villages, for all round development of

infrastructure, like roads, drainages, sanitation, electricity, sponsors religious activities &
constructions and provides safe drinking water facilities, with the installation of R.O.
water purification systems.
BUSINESS FOCUS
Active Pharmaceutical Ingredients

Hetero is one of the largest manufacturer and supplier of Active Pharmaceutical
Ingredients (APIs) catering to the ever increasing requirements of the global
pharmaceutical market.
The infrastructure available with Hetero for manufacturing of Active Pharmaceutical
Ingredients and the intermediate chemicals is one of the best, with State-of-the- Art
facilities designed to meet the global standards and cGMPs.
With 11 API manufacturing facilities in operation, Hetero has been able to manufacture
more than 200 APIs, and supply to different markets. 6 of the API facilities are approved
by USFDA, TGA, EU, PMDA, KFDA and WHO.
12
Hetero is a trusted supplier of several APIs in wide range of therapeutic categories and
the largest supplier of complete range in Antiretroviral products.
Hetero also has dedicated facility for manufacturing of Oncology products.
RESEARCH & DEVELOPMENT

Research & Development is the foundation of Heteros philosophy of developing costeffective, high quality and safe medicines to society. Hetero Research Foundation is one
of the most innovative, productive, and respected a scientific research organization which
is recognized by the Department of Science & Technology, Government of India.
Hetero Research Foundation (HRF) has a team of over 400 dedicated scientists working
in the areas of Process, Analytical and Discovery Research. R & D centre conforms to
international Standards and has advanced equipment for both basic and applied research.
Process R&D
HRF has developed process for 150 plus molecules for various markets. The R&D team
actively involved in process development, scaling-up technology transfer and associates
with manufacturing team throughout life cycle of product.HRF has always been
emphasizing to ensure that the processes being adopted for the products are cost
effective, safe to handle and with optimum advantage in terms of yield and quality.
Analytical R&D
Analytical research at HRF is equipped to conduct complete physical and chemical
characterisation of APIs/ NCEs. Further, the team is well versed with regulatory filings
and has vast experience in documentation. The infrastructure includes advanced
instruments like LC-MS-MS, GC-MS, NMR, Powder XRD apart from several HPLC
systems.
13
MANUFACTURING INFRASTRUCTURE
Hetero group as a whole has 18 Manufacturing facilities at various locations
encompassing manufacturing of Active Pharmaceutical Ingredients and Finished Dosage
Products.
Committed to quality, safety and environment, most of our manufacturing facilities have
been inspected and approved by the US FDA, WHO-Geneva, Spanish Agency of
Medicines & Health care products, ANVISA-Brazil, IDA-Netherlands etc.,
API Facilities
1. Hetero Drugs Ltd.
Unit I (Bonthapally):
API Manufacturing Facility for Regulatory Markets USFDA Approved
Unit IV (Bonthapally)
API Manufacturing Facility for Non-Regulatory & Domestic Markets
Unit VI (Vizag Non SEZ):

API Manufacturing Facility for Domestic Market & Semi-Regulatory Market
Unit VIII (Bonthapally - EOU):

API Manufacturing Facility - EOU
Unit IX (Vizag SEZ):

API Manufacturing Facility for Semi- Regulatory & Regulatory Markets
14
2. Hetero Labs Ltd.
Unit I (Kazipally):
API Manufacturing Facility for Regulatory Markets USFDA Approved
Unit III (Vizag Non SEZ):

API Manufacturing Facility for Domestic Markets
Unit IX (Vizag SEZ):

API Manufacturing Facility for Regulatory MarketsUSFDA Approval under
consideration
Formulation Facilities
1. HETERO LABS LTD.
Unit III (Jeedimetla):

Finished dosage manufacturing facility for regulatory markets USFDA, WHO,
ANVISA, GCC, ISO, MCC, Pharmacy Medicine and Poisons Board-MALAWI,
AEMPS & UAE Approved
Unit V (Baddi):
Finished dosage manufacturing facility for Indian market
Unit II (Baddi):
Finished dosage manufacturing facility for semi-regulatory & Indian markets
Unit V (Jedcherla):
Solid & Liquid finished dosage manufacturing facility for semi-regulatory &
regulatory markets - US FDA, WHO, PICS/GMP Approved
15
Unit VI (Jedcherla):
Dedicated Oncology finished dosage manufacturing facility for semi- regulatory
& regulatory markets - USFDA, PPB-Kenya, NDA-Uganda, NoMA Europe
(Norway), Zimbabwe, Namibia, Botswana, Malawi, ANVISA (Brazil) Tanzania,
TFDA (Taiwan), Ethiopia, Mexico & Belarus (MOH) Approved
16
PRODUCTS
API's - Regulated Market
Drugs Master Files
API Name
Status
Acyclovir
USDMF/EDMF
Adefovir Dipivoxil
USDMF/EDMF
Alfuzosin Hydrochloride
USDMF/EDMF
Alvimopan
USDMF
Amlodipine Besylate
USDMF/EDMF
Aripiprazole
USDMF/EDMF
Atomoxetine HCl
USDMF/EDMF
Atorvastatin Calcium Amorphous & Crystalline
USDMF/EDMF
Atovaquone
USDMF/EDMF
Azilsartan Medoxomil
USDMF/EDMF
Azithromycin Monohydrate
USDMF/EDMF
17
API Name
Status
Bupropion Hydrochloride
USDMF/EDMF
Candesartan Cilexetil
USDMF/EDMF
Celecoxib Form III
USDMF/EDMF
Cilazapril
EDMF/JPDMF
Citalopram HBr
USDMF/EDMF
Clopidogrel Bisulphate Form I & Form II
USDMF/EDMF
Colesevelam HCl
USDMF/EDMF
Cyclobenzaprine HCl
USDMF/EDMF
Dabigatran Etexilate Mesylate
USDMF/EDMF
Desloratadine
USDMF/EDMF
Dexlansoprazole
USDMF/EDMF
Donepezil HCl Form I & III
USDMF/EDMF
Dorzolamide HCl
USDMF/EDMF
Doxazosin Mesylate
EDMF
Doxercalciferol
USDMF/EDMF
18
API Name
Status
Duloxetine HCl
USDMF/EDMF
Dutasteride
USDMF/EDMF
Eletriptan Hydrobromide alfa Form
USDMF/EDMF
Eltrombopag Olamine
USDMF/EDMF
Entacapone Form A
USDMF/EDMF
Eprosartan Mesylate
USDMF/EDMF
Escitalopram Oxalate
USDMF/EDMF
Esomeprazole Mg Dihydrate / Trihydrate
USDMF/EDMF
Esomeprazole Sodium
USDMF/EDMF
Etoricoxib Form I
USDMF/EDMF
Ezetimibe
USDMF/EDMF
Famciclovir
USDMF/EDMF
Febuxostat
USDMF/EDMF
Felbamate
USDMF/EDMF
Fenofibrate
USDMF
19
API Name
Status
Fesoterodine Fumarate
USDMF
Fexofenadine Hydrochloride Form I & II
USDMF/EDMF
Finasteride Form I
USDMF/EDMF
Fingolimod Hydrochloride
USDMF/EDMF
Fosinopril Sodium
USDMF/EDMF
Gabapentin
USDMF/EDMF
Ganciclovir
USDMF/EDMF
Glimepiride
USDMF/EDMF
Hydralazine HCl
USDMF/EDMF
Irbesartan
USDMF/EDMF
Itraconazole
USDMF/EDMF
Lacosamide Form I
USDMF/EDMF
Lansoprazole
USDMF/EDMF
Lercanidipine HCl
EDMF
Levetiracetam
USDMF/EDMF
20
API Name
Status
Levofloxacin
USDMF/EDMF
Lisinopril
USDMF/EDMF
Loratadine
EDMF
Losartan Potassium Form I
USDMF/EDMF
Lurasidone Hydrochloride
USDMF/EDMF
Metaxalone
USDMF/EDMF
Milnacipran Hydrochloride
USDMF/EDMF
Montelukast Sodium
USDMF/EDMF
Moxifloxacin HCl Monohydrate / Anhydrous
USDMF/EDMF
Memantine Hydrochloride Form I
USDMF/EDMF
Nabumetone
USDMF/EDMF
Nebivolol HCl
EDMF
Olanzapine Form I & II
USDMF/EDMF
Olmesartan Medoxomil
USDMF/EDMF
Omeprazole Form A & Form B
USDMF/EDMF
21
API Name
Status
Omeprazole Magnesium
USDMF/EDMF
Oseltamivir Phosphate
USDMF/EDMF
Pantoprazole Sodium
USDMF/EDMF
Perindopril Erbumine Alfa form
USDMF/EDMF
Pioglitazone HCl
USDMF/EDMF
Pitavastatin Calcium Form H1
USDMF/EDMF
Pramipexole Di HCl
USDMF/EDMF
Prasugrel Hydrochloride Form B / Base
USDMF/EDMF
Pregabalin
USDMF/EDMF
Proguanil HCl
USDMF/EDMF
Prulifloxacin
USDMF/EDMF
Quetiapine Fumarate
USDMF/EDMF
Rabeprazole Sodium
USDMF/EDMF
Ramipril
USDMF/EDMF
Raloxifene Hydrochloride
USDMF/EDMF
22
API Name
Status
Riluzole
USDMF/EDMF
Risedronate Sodium
USDMF/EDMF
Rivastigmine Tartrate / Base
USDMF/EDMF
Rizatriptan Benzoate
USDMF/EDMF
Roflumilast
USDMF/EDMF
Rosuvastatin Calcium
USDMF/EDMF
Rufinamide
USDMF/EDMF
Saxagliptin Hydrochloride
USDMF/EDMF
Sertraline HCl Form I & II
USDMF/EDMF
Sevelamer Hydrochloride & Carbonate
USDMF/EDMF
Sildenafil Citrate
USDMF/EDMF
Simvastatin
USDMF/EDMF
Solifenacin Succinate
USDMF/EDMF
Silodosin Alfa Form
USDMF/EDMF
Telmisartan
USDMF/EDMF
23
API Name
Status
Terbinafine HCl
USDMF/EDMF
Tetrabenazine
USDMF/EDMF
Tolvaptan
USDMF/EDMF
Tolterodine Tartrate
USDMF/EDMF
Topiramate
USDMF/EDMF
Torsemide
USDMF/EDMF
Trandolapril
USDMF/EDMF
Valacyclovir HCl
USDMF/EDMF
Valganciclovir
USDMF/EDMF
Valsartan
USDMF/EDMF
Vilazodone Hydrochloride Amorphous & Premix
USDMF/EDMF
Voriconazole
USDMF/EDMF
Zolmitriptan
USDMF
Zonisamide
USDMF
Ziprasidone HCl
USDMF/EDMF
24
API Name
Status
ANTIRETROVIRAL
Abacavir Sulphate
USDMF/EDMF
Atazanavir Sulphate Type I & Form H1
USDMF/EDMF
Cobicistat
USDMF/EDMF
Darunavir Amorphous & Ethanolate
USDMF/EDMF
Didanosine
USDMF/EDMF
Dolutegravir Sodium
USDMF/EDMF
Efavirenz Form I & Form H1
USDMF/EDMF
Elvitegravir
USDMF/EDMF
Emtricitabine
USDMF/EDMF
Entecavir
USDMF/EDMF
Etravirine Form I
USDMF/EDMF
Fosamprenavir Calcium Form H1 & Amorphous
USDMF/EDMF
Lamivudine Form I & Form II
USDMF/EDMF
Lopinavir Form I & Amorphous
USDMF/EDMF
25
API Name
Status
Maraviroc Form B & Amorphous
USDMF/EDMF
Nevirapine
USDMF/EDMF
Raltegravir Potassium Form I & Amorphous
USDMF/EDMF
Ritonavir Form I & Amorphous Premix
USDMF/EDMF
Saquinavir Mesylate
USDMF/EDMF
Stavudine
USDMF/EDMF
Tenofovir Disoproxil Fumarate
USDMF/EDMF
Zidovudine
USDMF/EDMF
Boceprevir
Technical Package
Indinavir Sulphate
Technical Package
Nelfinavir Mesylate
Technical Package
Rilpivirine Hydrochloride
Technical Package
Telaprevir
Technical Package
ANTINEOPLASTICS
Abiraterone Acetate
USDMF/EDMF
26
API Name
Status
Anastrozole
USDMF/EDMF
Aprepitant
USDMF/EDMF
Bendamustine Hydrochloride
USDMF/EDMF
Bexarotene
USDMF/EDMF
Bicalutamide
USDMF/EDMF
Bortezomib
USDMF/EDMF
Capecitabine
USDMF/EDMF
Cyclophosphamide
USDMF/EDMF
Docetaxel
USDMF/EDMF
Erlotinib Hydrochloride Form A
USDMF/EDMF
Fosaprepitant Dimeglumine
USDMF/EDMF
Gefitinib
USDMF/EDMF
Gemcitabine HCl
USDMF/EDMF
Imatinib Mesylate Amorphous / Alfa Form / Beta Form
USDMF/EDMF
Irinotrcan HCl
USDMF/EDMF
27
API Name
Status
Lapatinib Ditosylate
USDMF/EDMF
Lenalidomide
USDMF/EDMF
Letrozole
USDMF/EDMF
Melphalan Hydrochloride
USDMF/EDMF
Nilotinib Hydrochloride
USDMF/EDMF
Paclitaxel
USDMF/EDMF
Pazopanib Hydrochloride
USDMF/EDMF
Pemetrexed Disodium 2.5 Hydrate / 7.0 Hydrate
USDMF/EDMF
Plerixafor
USDMF/EDMF
Pralatrexate
USDMF/EDMF
Sorafenib Tosylate
USDMF/EDMF
Sunitinib Malate
USDMF/EDMF
Temozolomide
USDMF/EDMF
Thalidomide
USDMF/EDMF
Zoledronic Acid
USDMF/EDMF
28
API Name
Status
Azacitidine
Technical Package
Carfilzomib
Technical Package
Carboplatin
Technical Package
Cisplatin
Technical Package
Oxaliplatin
Technical Package
Tamoxifene Citrate
Technical Package
Vandetanib
Technical Package
Table 1: Products by Hetero Healthcare Limited.
29
Technical Packages
API Name
Status
Ambrisentan
Technical Package
Avanafil
Technical Package
Bosentan
Technical Package
Brinzolamide
Technical Package
Carglumic Acid
Technical Package
Cevimeline Hydrochloride
Technical Package
Cinacalcet Hydrochloride
Technical Package
Cilnidipine
Technical Package
Dalfampridine
Technical Package
Dapagliflogin
Technical Package
Deferasirox
Technical Package
Desvenlafaxine Succinate
Technical Package
Eplerenone
Technical Package
Eslicarbazepine
Technical Package
30
API Name
Status
Gabapentin Enacarbil
Technical Package
Ibandronate Sodium
Technical Package
Ivabradine Hydrochloride Premix
Technical Package
Linagliptin
Technical Package
Naftopidil
Technical Package
Olopatadine HCl
Technical Package
Oxcarbazepine
Technical Package
Pirfenidone
Technical Package
Posaconazole
Technical Package
Ramelteon
Technical Package
Ranolazine
Technical Package
Rupatadine Fumarate
Technical Package
Sitagliptin Phospate
Technical Package
Tadalafil
Technical Package
Tofacitinib Citrate
Technical Package
31
API Name
Status
Trospium Chloride
Technical Package
Vardenafil HCl
Technical Package
Vigabatrin
Technical Package
Table 2: Technical Packages by Hetero Heathcare Limited.
KEY PARTNERS
Global health group is engaged in research, development, manufacture and marketing of

healthcare products. The main activities according their importance and their turnover
are:
Pharmaceuticals (prescription drugs, consumer health, general medicine): aging diabetes,
rare diseases, oncology and other important products in the prevention of thrombosis,
cardiovascular disease, nephrology and biosurgery.
R&D to prevent, treat and cure disease. Constant innovation is very important in order to
attain his goal: answer to the real needs of patients and provide them appropriate
therapeutic solutions
Clinical Development Marketing & Distribution Creating value through partnerships
availability and performance of drugs.
32
CUSTOMER CHANNELS
Communication through Medical Institutions : hospitals, pharmacies, health personnel
(doctors) Communication through a website heterohealthcare.com and social media as
Facebook, Twitter, Android, iPhone and iPad app, YouTube Channels.
Hetero Healthcare has also developed a wide network of industrial sites. Commercial
presence in the world and multiple acquisitions and partnerships.
CUSTOMER SEGMENT
Physical Patients Health professionals: doctors, hospitals, pharmaceutical customer. Offer
training and services: Hetero assists health professionals throughout their careers and in
the evolution of their profession General public: self medication (one of the growth
platforms for Hetero) Veterinarians, farmers and pet owners Universities and students
(through training) Worldwide connected network of selected partners
Geographical Patients around the world Present in 100 countries and its products are
distributed in more than 170 countries Hetero is recognized in Emerging Markets, with
excellent positions in major countries.
CUSTOMER RELATIONSHIP
Innovation with the Doctors: Conference calls and Interactive learning sessions. Website
Destinated to all their clients worldwide, it helps Hetero Healthcare to defend a
healthcare and public utility image.
33
COST STRUCTURE
R&D is NOT the main cost item: They try to optimise their resources allocation in order
to maximize the R&D return on investment, Partnerships and Acquisitions: Investment
for 26 new transactions (8 acquisitions and 18 partnerships in R&D) Sales Force is the
1st cost item: Re-allocation by region and by products (less expenses on traditional
products but more on innovative ones)
Administrative and General Charges: Methodological following of these costs,
Communication and Publicity: By definition publicity is free and better for the
companys image Ex: Press articles on the last Heteros innovation which will be able to
cure a rare diseases.
In emerging market the main cost are: Purchase of raw material Energy consumption of
the laboratories Work force
REVENUE STREAMS
Asset Sales type of revenue- Hetero provides innovative products and communication
related to those new medicines. The company contributes to the medicines promotion by
the States. Worldwide Net Turnover Shares: Domestic Market- 76%, International
Market-24%.
34
EVENTS
April'2010
Hetero launches one of the Indias largest finished dosage manufacturing facility in
Special Economic Zone (SEZ) at Jadcherla.
Hetero launches its new formulation facility (SEZ) at Jadchelra, Andhra Pradesh, India.
Strategically located just 60 kilometers from Hyderabad International airport off NH 7,
the project situated in the states first green industrial park.
The total unit area is 75 acres and with two manufacturing facilities. This facility offers a
huge production capacity of 18 billion tablets and capsules per annum. It has a dedicated
Oncology facility with a production capacity of 200 million tablets & capsules, 15
million liquid injectable vials & 15 million lyophilised Injectables.
This World-class facility is meeting the cGMP and regulatory requirements, with
integrated quality management system in place. All quality control Instruments are 21CFR compliant. Walk in type stability chambers with global requirements for stability
study and Integrated building management system from Honey well -USA , Lyophilizer
VIRTIS -USA, Liquid Filling machine from BOSCH Germany, makes this
manufacturing facility at par with the best in the world.
April'2010
Hetero receives tentative approval for Tenofovir disoproxil fumarate tablets from
USFDA
Hetero is pleased to announce that it has received the tentatively approval for Tenofovir
disoproxil fumarate from the US Food & Drug Administration (USFDA).
Tenofovir tablets 300 mg is generic equivalent to Viread tablets 300 mg of Gilead
Sciences. Tenofovir belongs to a class of antiretroviral drugs known as nucleotide
35
analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an

enzyme crucial to viral production in HIV-infected people. Tenofovir is indicated in
combination with other antiretroviral agents for the treatment of HIV-1 infection in
adults.
Nov'2009
Hetero receives tentative approval of Lamivudine and Tenofovir fixed dose
combination tablets, 300mg/300mg tablets from USFDA
On November 5, 2009, using expedited review procedures developed to support the
President's Emergency Program For AIDS Relief (PEPFAR1), the US Food and Drug
Administration (FDA), granted tentative approval for lamivudine and tenofovir disoproxil
fumarate fixed dose combination tablets, 300mg/300mg.
The fixed dose combination product, indicated for use in combination with other
antiretrovirals for the treatment of HIV-1 infection.
36
SWOT ANALYSIS OF HETERO HEALTHCARE LIMITED

SWOT Analysis
1. Hetero Healthcare Ltd is worlds largest global producer of
anti-retroviral drugs for the treatment of HIV/AIDS.

2. Hetero Healthcare Ltd is recognized as a world leader in
process chemistry, API manufacturing, formulation
development, manufacturing and commercialization.
3. Hetero Healthcare Ltd is research-driven pharmaceutical
company.
Strength
4 is recognized as one of the top 10 companies in the Indian

pharmaceutical industry with an annual turnover of US$ 1.2
billion.
5. Hetero Healthcare Ltd has 15,000 employees.
6. Hetero healthcare manufactures high-quality drugs.
7. National award for "Best Efforts in Research and
Development" from the Department of Scientific and

Industrial Research, Ministry of Science and Technology,
Government of India, in the year 1996.
Weakness
1. Controversies regarding issue of compulsion of licensing

in India
37
2. Patent expiry for a number of API products

1. Strategic agreements with other pharmaceutical companies
and organizations to boost its research.
Opportunity
2. Increasing awareness about healthcare needs

3. Increasing demand for quality healthcare solutions
1.Risk of unsuccessful new Products
Threats
2.Regulatory environment is becoming more & more

stringent
3.Economic slowdown in European markets
Competition
1. Abbott Laboratories
2. Amgen
Competitors
3. AstraZeneca
4. Bristol-Myers Squibb
5. Johnson & Johnson
6. Merck
7. Novartis
8. Pzer
9. Roche Holdings
10. Sun Pharma
38
SWOT ANALYSIS OF PFIZER
SWOT Analysis
1. One of the largest pharmaceutical company in the world
and spread over more than 50 countries.
2. Excellent research and development (R&D) creating
innovative and breakthrough products
Strength
3. Mergers and acquisitions with big pharma brands

increasing brand reputation
4. Has over 100,000 employees as a part of the organization
5. Strong brand name and recall globally
Tough competition from other major pharma brands means
limited scope for market share growth
Weakness
Negative brand image due to involvement in largest

healthcare fraud of marketing its drug illegally
1.Strategic agreements with other pharmaceutical companies
and organizations to boost its research.
Opportunity
2. Increasing awareness about healthcare needs

3. Global penetration through mergers and acquisitions
4. Increasing demand for quality healthcare solutions
Threats
1.Risk of unsuccessful new Products

2.Regulatory environment is becoming more & more
39
stringent
3.Economic slowdown in European markets
Competition
1. Abbott Laboratories
2. Amgen
3. AstraZeneca
4. Bristol-Myers Squibb
5. Johnson & Johnson
Competitors
6. Merck
7. Novartis
8. Roche Holdings
9. Sun Pharma
10. Hetero Healthcare
40
DATA ANALYSIS AND INTERPRETATION

I.
II.
III.
Source of data: Primary

*Data collection Instrument: Direct interview through questionnaire
Sampling plan:
Time taken: 40 days
Area covered: Western and central Mumbai
IV.
Observation: Female doctors dont treat the patients of Benign Prostate

Hyperplasia, they treat mostly patients with Over Active Bladder.
Over Active Bladder is mostly misunderstood for the Urinary Tract Infection but
this case is only seen in females than in males. The differential diagnose of the
Over Active Bladder is Urinary Tract Infection.
41
QUESTIONNAIRE AND ANALYSIS

UROLOGY QUESTIONNAIRE
1. Do you see patients for Benign Prostatic Hyperplasia (BPH) and Over Active
Bladder (OAB)
BPH: Yes - 239 No 33
OAB: Yes 270 No 2
300
250
200
Yes
150
No
100
50
0
BPH
OAB
Figure 1: Count of Patients suffering from BPH & OAB
Analysis:
Out of 272 respondent doctors, 239 treats patients for BPH and 33 dont treat patients
for BPH & 270 treats patients for OAB and 2 do not treat patients for OAB.
42
2. How do you diagnose patients for BPH and OAB?

BPH: USG 243, PSA 78, Clinical test 47, KUB 7, urine culture- 9
OAB: Cystometry 79, USG 187, Clinical test 46, Urine culture 16,
250
200
150
100
BPH
50
0
USG
PSA
Clinical
test
KUB
BPH
Figure 2: Diagnostic Procedure for BPH
43
200
150
100
OAB
50
0
USG
Clinical Test
Cystometry
OAB
Urine
culture
Figure 3: Diagnostic Procedure for OAB
Analysis:
For BPH: 243 patients are diagnosed by USG, 78 by PSA, 47 by clinical test, 7 are
diagnosed by KUB.
For OAB: 187 patients are diagnosed by USG, 79 by Cystometry, 46 for Clinical test and
16 by Urine culture
.
44
3. Do you treat patients by yourself or recommend to Urologist/Gen Surgeons?

Treat Self 1
Recommend to Urologist - 19
Both 252
Treatment
300
200
100
Treatment
0
Treat Self
Recommend
to Urologist
Treatment
Both
Figure 4: Line of Treatment
Analysis:
252 Doctors said that they treat Self and then recommend the patients to urologist (Both),
19 Doctors recommends the patients directly to the Urologist, 1 treated by self, some said
it depends on cases-to- cases.
45
4. If the Doctors treat patients by himself then How do you treat your patients
for BPH and OAB? (Name of the Molecule/single or combination)
BPH
160
140
120
100
80
60
40
20
0
BPH
BPH
Figure 5: Molecules used by GP's for BPH
46
OAB
80
60
40
20
0
OAB
OAB
Figure 6: Molecules used by GP's for OAB
Analysis:
For BPH:
For OAB:
Tamsulosin 156
Flavoxate 57
Tamsulosin + Dutasteride 26
Drotaverine 27
Finasteride 10
Dutasteride 12
Doxazosin 6
Tolterodine 66
Finasteride + Tamsulosin 7
Tamsulosin 61
Prazosin 1
Fesoterodine 6
Oxybutinin 10
Trospium 5
Tamsulosin + Dutasteride 6
Solfinacen- 2
47
5. How long do you recommend the treatment for BPH and OAB patients?
(Few months or Lifelong)
BPH
100
80
60
40
20
0
BPH
BPH
Figure 7: Dosage and Period Molecule for BPH
48
OAB
90
80
70
60
50
40
30
20
10
0
OAB
Few 1 month
months
2
months
3
months
6
Life Long
Depends
months
upon the
cases
OAB
Refer to
urologist
Figure 8: Dosage and Period Molecule for OAB
Analysis:
For BPH:
For OAB
Few months 63
Few Months 47
1 month 93
1 month 40
2 months 11
2 month 4
3 months 18
3 months 4
6 months 20
6 months 11
Life Long -10
Lifelong 88
Depends upon the cases 19
Depends upon the cases 33
Surgical Intervention -6
Refer To the Urologist 2
49
6. How do you update yourself for BPH/OAB for latest information on its
management?
CMES and Medical journal- 253
Internet 95
Seminars 9
Mobile app 2
300
250
200
150
100
50
0
Cmes and
Medical Journal's
Internet
Mobile App
Seminars
Figure 9: Awareness among GPs regarding BPH & OAB
Analysis:
Out of 273 Doctors 253 update their self through CMES and Medical Journals, 95
through internet, 9 through seminars and 2 Doctors through mobile app.
50
FINDINGS
There are already many products containing Tamsulosin and Dutasteride in

market since past 10 years
The product which is yet to be launched is already the leading brand of

competitors.
Physicians already prescribing this product so there are rare chances they will
write this product.
Female Physicians dont treat the patients of Benign Prostate Hyperplasia (BPH)
which will further reduce the sales of this product.
The competitors are very renowned Pharmaceutical Companies as compared to

Hetero Healthcare Ltd.
The patients suffering from BPH and OAB are treated within the time period of 3
to 12 months.
The most commonly observed are Nocturia, Haemeturia, Urge incontinence in

BPH patients, whereas, Urgency, Frequency, Micturition, Incontinence,
Incomplete emptying of Bladder are symptoms of Patient suffering from OAB.
Physicians Update themselves about these disease through CMES, Medical

Journals, Urology Seminars and sometimes Internet.
Some Physicians treat this disease themselves or refer to Urologist directly while
many Physicians first treat the patients themselves and if not cured than referred
to urologist.
Some Physicians referred their patients to nephrologist only if surgical

intervention was necessary.
The most commonly opted diagnostic methods were USG i.e. Ultra Sono Graphy,
PSA i.e. Prostate - Specific Antigen test, KUB test i.e. Kidney Ureter and Bladder
test before and after emptying the Bladder and Cystometry.
Urinary Tract Infection was the differential diagnosis observed so maximum

times an antibiotic along with diuretic was prescribed.
The most prescribed molecule by Physicians was Tamsulosin for both BPH and
OAB.
51
STRATEGY
The product should be launched as per the Physicians and Retailers convenience
The product should contain both the molecules, Tamsulosin and Dutasteride such
that one product will be used to treat both the disease.
In order to beat the competitors the vital aspects like pricing, distribution channel,
retailers margin and Physicians convenience should be kept in mind.
The product should be launched with a clear mindset of volume sales or Value
sales as later decision might prove to be fatal.
Before launching the product, awareness should be created by distribution of free

samples among the Physicians and the retailers.
As this similar molecule is in market since past 10 years so the product power,
product efficacy, shelf life should be elevated than the competitor products which
will give the reason to the retailers to stock the product without the fear of
expiration.
Physicians should be provided with vital reasons and percussions to write the
product, as without their prescriptions product will not move efficiently in the
market.
52
CONCLUSIONS
Creating awareness at this stage when the other Pharmaceuticals Companies already have
this molecule in market is nothing but the risky decision.
To elevate the sales the product should be established as a brand first, as per the survey
the product is too old to launch in the market.
The product has certain hazardous side effects which is one factor of slow moving of this
molecule since past 10 years.
The survey was conducted at General Physicians level however; this product is actually
meant for the Nephrologist and Urologist platform.
General Physicians cover only 5 to 6 patients per month so launching this Product at
General Physicians level might prove to fatal.
This molecule is used only for the long term treatment and from survey it is evident that
General Physicians are prescribing this molecule for 3 to 12 months.
Many patients do not visit the General Physician again if they are not cured and satisfied
with the treatment given hence the Physician doesnt knows whether the patient is cured
or he is consulting the specialist.
From this entire survey I conclude that the product is not fit to be launched under such
circumstances as the product doesnt have any uniqueness as compared to the
competitors product, it doesnt have any such innovative combination or molecule which
will enhance the sales.
53
BIBLIOGRAPHY
www.heterodrugs.com
Essentials of Pharmacotherapeutics by F.S.K. Barar S. Chand Publishing.
Rang and Dales Pharmacology.
Text book of Medical Physiology by Guyton and Hall.
www.wikipedia.com
www.webmd.com
54

Hetero

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Hetero

Uploaded by

Copyright:

Available Formats

A

Under the guidance of

The research on Awareness and Treatment trends amongst General Physicians

Awareness and Treatment trends amongst General Physicians about Benign

Background of Pharma Industry

Introduction to Hetero Healthcare Limited

SWOT Analysis of Hetero Healthcare

SWO T Analysis of Pfizer Limited

Data Analysis & Interpretation

Questionnaire & Analysis

Benign Prostate Hyperplasia:

infections or neurological conditions to be excluded. The amount of urine passed during

BACKGROUND OF PHARMA INDUSTRY

INTRODUCTION TO HETERO HEALTHCARE LIMITED

Hetero is a research based global pharmaceutical company focused on development,

AWARDS AND ACCOLADES

Top Pharmexcil Gold Patent award.

Top Pharmexcil Outstanding Export Performance award in Drugs and

Chemexil Trishul export award for outstanding export performance 2001

Highest exporter award against stiff competition from internationally recognized

Top Chemexil award for Exports.

CORPORATE SOCIAL RESPONSIBILITY

Completed One Million Plantation Programme.

Taking up Plantation in the surrounding Schools.

Rizvi Institute of Management Studies & Research

Provided substantial amount to the industrial association for the development of

Provision of Biomass Pellets for cooking purpose in place of LPG gas.

Social Welfare Programs:

Infrastructure: Construction and renovation of schools, classrooms, libraries,

Distribution of booksand reading materials to the school libraries along with

Awarding of Merit scholarships to students and provision of free technical

2) Sports: Sponsors athletes from various educational institutions to participate in

4) Rural Infrastructure: Hetero adopts villages, for all round development of

Active Pharmaceutical Ingredients

RESEARCH & DEVELOPMENT

Unit VI (Vizag Non SEZ):

Unit VIII (Bonthapally - EOU):

Unit IX (Vizag SEZ):

2. Hetero Labs Ltd.

Unit III (Vizag Non SEZ):

Unit IX (Vizag SEZ):

Unit III (Jeedimetla):

Rizvi Institute of Management Studies & Research

API's - Regulated Market

Drugs Master Files

Atorvastatin Calcium Amorphous & Crystalline

Celecoxib Form III

Clopidogrel Bisulphate Form I & Form II

Dabigatran Etexilate Mesylate

Donepezil HCl Form I & III

Eletriptan Hydrobromide alfa Form

Esomeprazole Mg Dihydrate / Trihydrate

Fexofenadine Hydrochloride Form I & II

Losartan Potassium Form I

Moxifloxacin HCl Monohydrate / Anhydrous

Memantine Hydrochloride Form I

Olanzapine Form I & II

Omeprazole Form A & Form B

Perindopril Erbumine Alfa form

Pitavastatin Calcium Form H1

Prasugrel Hydrochloride Form B / Base

Rivastigmine Tartrate / Base

Sertraline HCl Form I & II